Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Corporate News: PATRIZIA SE (EQS) +++ PATRIZIA Aktie +3,58%

INNOCAN Aktie

 >INNOCAN Aktienkurs 
1.04 EUR    -3.3%    (TradegateBSX)
Ask: 1.125 EUR / 830 Stück
Bid: 1.035 EUR / 920 Stück
Tagesumsatz: 1259 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
INNOCAN Aktie über LYNX handeln
>INNOCAN Performance
1 Woche: -11,6%
1 Monat: -16,7%
3 Monate: -31,7%
6 Monate: -72,2%
1 Jahr: -90,4%
laufendes Jahr: -75,1%
>INNOCAN Aktie
Name:  INNOCAN PHARMA CORP.
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA45783P5085 / A41FTP
Symbol/ Ticker:  IP40 (Frankfurt)
Kürzel:  FRA:IP40, ETR:IP40, IP40:GR
Index:  -
Webseite:  https://innocanpharma.com..
Profil:  InnoCan Pharma Corporation is a pharmaceutical technology company founded in 2018 and headquartered in Calgary, Canada. It specializes in innovative drug delivery platforms that combine cannabidiol (CBD) with other pharmaceutical ingredients to treat..
>Volltext..
Marktkapitalisierung:  5.49 Mio. EUR
Unternehmenswert:  3.57 Mio. EUR
Umsatz:  20.53 Mio. EUR
EBITDA:  -2.97 Mio. EUR
Nettogewinn:  -0.81 Mio. EUR
Gewinn je Aktie:  -0.18 EUR
Schulden:  1.49 Mio. EUR
Liquide Mittel:  5.78 Mio. EUR
Operativer Cashflow:  -1.35 Mio. EUR
Bargeldquote:  3.29
Umsatzwachstum:  -20.11%
Gewinnwachstum:  42.67%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  INNOCAN
Letzte Datenerhebung:  09.11.26
>INNOCAN Kennzahlen
Aktien/ Unternehmen:
Aktien: 4.5 Mio. St.
Frei handelbar: 77.34%
Leerverk. Aktien: -
Rückkaufquote: 0.07%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: No rating
Kursziel: -
Bewertung:
KGV: -
KGV lG: -
KUV: 0.25
KBV: 1.18
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 90.45%
Gewinnmarge: -3.94%
Operative Marge: -14.6%
Managementeffizenz:
Gesamtkaprendite: -8.6%
Eigenkaprendite: -20.39%
>INNOCAN Peer Group
Gesundheit, Cannabis- Produkte, Neurologische Erkrankungen/ Schlaganfälle
 
29.09.26 - 22:09
 VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA (PR Newswire)
 
HERZLIYA, Israel and CALGARY, Alberta, Sept. 29, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., its consumer wellness subsidiary, is pleased to announce that VALITIC™ will be represented at Shoptalk......
23.09.26 - 22:12
 Innocan Pharma Announces First Tranche Closing of Private Placement of Units (PR Newswire)
 
HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that, further to its press release of September 9, 2026, it has complete a private placement of 247,314......
09.09.26 - 22:54
 Innocan Pharma announces up to C$1M private placement of units (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.09.26 - 22:39
 Innocan Pharma Announces Private Placement of Units (PR Newswire)
 
HERZLIYA, Israel and CALGARY, Alberta, Sept. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a private placement of up to 535,000 units of the Company (the "Units") at a......
31.08.26 - 22:09
 Innocan Pharma reports Q2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.08.26 - 22:03
 Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M) (PR Newswire)
 
Second Quarter 2026 Results: Gross Margin of 90.9% and Category Leadership HERZLIYA, Israel and CALGARY, Alberta, Aug. 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), today reported today 2026 financial consolidated results for......
05.08.26 - 15:33
 Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust (PR Newswire)
 
Milestone underscores strong consumer confidence, exceptional product quality, and the Company's expanding presence in the U.S. consumer wellness market HERZLIYA, Israel and CALGARY, Alberta, Aug. 5, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or......
29.07.26 - 22:06
 Valitic Surpasses 2 Million Trusted Customers, Marking a Major Milestone in Its Consumer Wellness Growth (PR Newswire)
 
The rapidly growing skincare brand continues to strengthen its position in the U.S. beauty market through innovation, quality, and customer trust. HERZLIYA, Israel and CALGARY, AB, July 29, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan"......
27.05.26 - 22:30
 Innocan Pharma reports Q1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.05.26 - 22:03
 Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, May 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its......
06.05.26 - 22:03
 Innocan Pharma LPT-CBD is featured in Pain Medicine News (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, May 6, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries is pleased to announce that its novel Liposomal Delivery Platform for......
06.04.26 - 12:57
 Innocan Pharma Announces Closing of Additional Debenture (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, April 6, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of an additional debenture of the Company (the......
02.04.26 - 20:12
 Innocan Pharma reports FY results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.03.26 - 16:21
 Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest......
31.03.26 - 09:03
 Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce......
16.03.26 - 22:07
 Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, March 16, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of a debenture of the Company (the "Debenture") to its......
11.03.26 - 23:45
 Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, March 11, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest......
27.02.26 - 22:33
 FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary......
09.02.26 - 17:01
 Innocan Pharma gibt Ergebnisse einer randomisierten, verblindeten klinischen Studie mit Hunden bekannt: LPT-CBD ist Placebo bei Schmerzlinderung überlegen (IRW Press)
 
Herzliya, Israel und Calgary, Alberta 9. Februar 2026 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP40) (OTCQB: INNPD) (Innocan oder das Unternehmen), ein Vorreiter auf dem Gebiet der......
09.02.26 - 15:12
 Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs (PR Newswire)
 
HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es gibt Tage, da geht alles schief. Umso schöner ist es, wenn man weiß, daß man bedingungslos geliebt wird. - James Morgan
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!